Table 1.
Characteristics of Patients
| Factors | Median (Range) or Number |
|---|---|
| Age | 76 (38–88) |
| Male/female | 21/6 |
| Etiology (HCV/HBV/NBNC) | 10/5/12 |
| ECOG-PS | 1 (0–3) |
| BCLC stage (B/C) | 23/4 |
| Child–Pugh A/B | 19/8 |
| Platelet (×104/µL) | 11.5 (5.7–47.9) |
| Serum creatinine (mg/dL) | 0.77 (0.47–1.30) |
| Serum albumin (g/dL) | 3.3 (2.2–4.2) |
| Serum total bilirubin (mg/dL) | 0.7 (0.4–2.0) |
| Prothrombin activity (INR) | 1.03 (0.95–1.32) |
| mALBI grade (1/2a/2b/3) | 5/7/11/4 |
| Alpha fetoprotein (ng/mL) | 50.4 (2.4–35768) |
| Tumor max size (cm) | 2.5 (1–10) |
| Tumor number | 4 (1–13) |
| Up-to-seven (in/out) | 12/15 |
| Prior c-TACE number | 2 (1–8) |
Abbreviations: HCV, hepatitis C virus; HBV, hepatitis B virus; NBNC, nonHBV nonHCV; ECOG-PS, Eastern Cooperative Oncology Group—Performance status; BCLC, Barcelona Clinic Liver Cancer; INR, international normalized ratio; mALBI, modified albumin-bilirubin; c-TACE, conventional transcatheter arterial chemoembolization.